Ingevity (NYSE:NGVT) Updates FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance: Ingevity set EPS guidance of 4.70–5.20 (vs. consensus 4.85) and revenue guidance of $1.1B–$1.2B (vs. consensus $1.2B), signaling revenue guidance slightly below Street expectations.
• Recent quarter missed estimates: The company reported $0.58 EPS (vs. $0.74 expected) and $255.1M revenue (vs. $257.3M expected), with quarterly revenue down 3.2% year‑over‑year.
• Market view and ownership: Analysts are mixed (consensus rating: Hold, $80 price target) while institutional investors own about 91.6% of the stock, with several large funds recently increasing stakes.

Ingevity (NYSE:NGVT - Get Free Report) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.700-5.200 for the period, compared to the consensus earnings per share estimate of 4.850. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. BMO Capital Markets reiterated an "outperform" rating and set a $83.00 target price on shares of Ingevity in a report on Monday, March 2nd. Wells Fargo & Company upped their target price on Ingevity from $65.00 to $75.00 and gave the stock an "equal weight" rating in a report on Friday, February 27th. Wall Street Zen cut Ingevity from a "buy" rating to a "hold" rating in a research report on Saturday, April 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Ingevity in a research report on Tuesday, April 21st. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $82.00 price target on shares of Ingevity in a research report on Thursday, February 26th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $80.00.

Ingevity Stock Performance

NGVT traded up $0.75 during mid-day trading on Wednesday, reaching $77.85. 281,746 shares of the company traded hands, compared to its average volume of 312,634. The stock has a market capitalization of $2.75 billion, a P/E ratio of -16.74 and a beta of 1.24. The company has a quick ratio of 0.79, a current ratio of 1.33 and a debt-to-equity ratio of 39.10. The company's fifty day moving average price is $71.00 and its 200-day moving average price is $63.85. Ingevity has a 52-week low of $36.47 and a 52-week high of $79.29.

Ingevity (NYSE:NGVT - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $0.74 by ($0.16). The company had revenue of $255.10 million for the quarter, compared to analysts' expectations of $257.27 million. Ingevity had a negative net margin of 13.51% and a positive return on equity of 126.25%. Ingevity's quarterly revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.95 earnings per share. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. On average, sell-side analysts expect that Ingevity will post 5.05 EPS for the current year.

Institutional Investors Weigh In On Ingevity

A number of hedge funds have recently added to or reduced their stakes in NGVT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Ingevity by 311.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company's stock valued at $23,769,000 after buying an additional 454,579 shares during the last quarter. Simcoe Capital Management LLC increased its stake in shares of Ingevity by 188.8% in the 2nd quarter. Simcoe Capital Management LLC now owns 624,935 shares of the company's stock worth $26,928,000 after purchasing an additional 408,508 shares in the last quarter. Boston Partners increased its stake in shares of Ingevity by 141.6% in the 4th quarter. Boston Partners now owns 620,360 shares of the company's stock worth $36,719,000 after purchasing an additional 363,584 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Ingevity by 137.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 424,038 shares of the company's stock worth $25,095,000 after purchasing an additional 245,620 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Ingevity by 217.4% in the 3rd quarter. Marshall Wace LLP now owns 228,201 shares of the company's stock worth $12,594,000 after purchasing an additional 156,301 shares in the last quarter. 91.59% of the stock is currently owned by hedge funds and other institutional investors.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.